Pfizer reports nearly $37 billion in COVID-19 vaccine sales in 2021

Published



Pfizer reported a total of $36.78 billion in global direct sales and alliance revenue from its two-dose COVID-19 vaccine in 2021 and intends to top that incredible amount of revenue this year.

In an earnings report released Tuesday, the company said it expects to reach $54 billion in sales in 2022 with two projects aimed at the health crisis: $32 billion in gross revenue for the vaccine and $22 billion in gross revenue for its COVID-19 antiviral treatment, Paxlovid.

Trusted reporting.Unlimited access.

Subscribe for full access to Washington Examiner coverage, expert political analysis, and subscriber-only journalism.

Get Unlimited Access

Already a member? Log in

Cancel anytime.